Stockreport

Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022 [MarketWatch]

Avenue Therapeutics, Inc.  (ATXI) 
Last avenue therapeutics, inc. earnings: 8/14 07:30 am Check Earnings Report
PDF the "Company"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced that the FDA has informed the Company that a joi [Read more]